Takeda Pharmaceutical (TAK) Gross Profit (2017 - 2026)

Takeda Pharmaceutical has reported Gross Profit for 10 years, with the latest figure at $5.1 billion in Q2 2026.

• On a quarterly basis, Gross Profit fell 5.56% year-over-year to $5.1 billion in Q2 2026; TTM through Jun 2026 was $30.6 billion, a 0.79% decrease from a year earlier, with the FY2026 full-year figure at $5.2 billion, down 3.79% from the prior year.
• Gross Profit was $5.1 billion for Q2 2026 at Takeda Pharmaceutical, down from $5.2 billion in the prior quarter.
• The five-year high for Gross Profit was $15.8 billion in Q3 2025, with the low at $4.4 billion in Q4 2024.
• Average Gross Profit over 5 years is $7.4 billion, with a median of $5.4 billion recorded in 2022.
• The largest YoY upside for Gross Profit was 199.34% in 2022 against a maximum downside of 16.72% in 2022.
• Over 5 years, Gross Profit stood at $4.6 billion in 2022, then slipped by 1.17% to $4.5 billion in 2023, then retreated by 2.35% to $4.4 billion in 2024, then advanced by 1.36% to $4.5 billion in 2025, then grew by 13.99% to $5.1 billion in 2026.
• The last three Gross Profit figures came in at $5.1 billion (Q2 2026), $5.2 billion (Q1 2026), and $4.5 billion (Q4 2025), per Business Quant data.